• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.恢复期血浆在免疫功能低下和脆弱人群中预防和治疗 SARS-CoV-2 的潜在用途。
Expert Rev Vaccines. 2022 Jul;21(7):877-884. doi: 10.1080/14760584.2021.1932475. Epub 2021 May 27.
2
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
3
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.免疫抑制患者 COVID-19 的门诊治疗与疫苗加强恢复期血浆治疗。
mBio. 2024 May 8;15(5):e0040024. doi: 10.1128/mbio.00400-24. Epub 2024 Apr 11.
4
Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.病例报告：恢复期血浆治疗后逐步出现抗炎和抗SARS-CoV-2作用并实现完全临床康复
Front Immunol. 2021 Apr 21;12:613502. doi: 10.3389/fimmu.2021.613502. eCollection 2021.
5
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.SARS-CoV-2 中和在恢复期血浆和商业的血浆衍生免疫球蛋白产品中。
BioDrugs. 2022 Jan;36(1):41-53. doi: 10.1007/s40259-021-00511-9. Epub 2021 Nov 29.
6
Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.免疫功能低下的奥密克戎 BA.1 或 BA.2 感染患者的恢复期血浆治疗。
Influenza Other Respir Viruses. 2024 Mar;18(3):e13272. doi: 10.1111/irv.13272.
7
The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness.恢复期血浆和免疫球蛋白在 COVID-19 大流行中的作用，包括对未来准备工作的影响。
Front Immunol. 2024 Sep 9;15:1448720. doi: 10.3389/fimmu.2024.1448720. eCollection 2024.
8
Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma.从 COVID-19 恢复期血浆中开发和表征抗 SARS-CoV-2 静脉用免疫球蛋白。
Immunotherapy. 2022 Oct;14(14):1133-1147. doi: 10.2217/imt-2022-0015. Epub 2022 Jul 27.
9
Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants.康复期血浆和超免疫球蛋白针对新冠病毒BQ.1、BQ.1.1和XBB变体的治疗潜力
J Clin Invest. 2023 Apr 17;133(8):e168583. doi: 10.1172/JCI168583.
10
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.病例报告：双滤过血浆置换获得的抗 SARS-CoV-2 恢复期抗体的作用。
Front Immunol. 2021 Jun 30;12:711915. doi: 10.3389/fimmu.2021.711915. eCollection 2021.

引用本文的文献

1
Cytokine, Anti-SARS-CoV-2 Antibody, and Neutralizing Antibody Levels in Conventional Blood Donors Who Have Recovered from COVID-19.从新冠病毒感染中康复的常规献血者体内的细胞因子、抗SARS-CoV-2抗体及中和抗体水平
Transfus Med Hemother. 2023 Sep 22;51(3):175-184. doi: 10.1159/000531942. eCollection 2024 Jun.
2
Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report.联合抗病毒治疗作为严重急性呼吸综合征冠状病毒2感染期间异基因造血干细胞移植的有效可行选择：一例病例报告
Front Oncol. 2024 Feb 13;14:1290614. doi: 10.3389/fonc.2024.1290614. eCollection 2024.
3
The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review.恢复期血浆在 COVID-19 中的作用：大流行后的结论性综述。
Life (Basel). 2023 Dec 11;13(12):2322. doi: 10.3390/life13122322.
4
What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral load evolution and immune response.我们从一名接受过两次肾移植的COVID-19患者的恢复期血浆治疗病例中学到了什么？一篇从病毒载量演变和免疫反应角度出发的病例报告。
Front Nephrol. 2023 Jun 23;3:1132763. doi: 10.3389/fneph.2023.1132763. eCollection 2023.
5
Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review.新冠疫情期间恢复期血浆疗法（CCP）的有效性：文献综述
J Blood Med. 2023 Feb 22;14:159-187. doi: 10.2147/JBM.S397722. eCollection 2023.
6
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.COVID-19 恢复期血浆治疗免疫功能低下患者：系统评价和荟萃分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
7
Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines.肿瘤血液科患者新冠康复期血浆治疗：呼吁修订欧洲白血病感染会议-9（ECIL-9）指南
J Clin Virol Plus. 2023 Feb;3(1):100128. doi: 10.1016/j.jcvp.2022.100128. Epub 2022 Dec 6.
8
Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe.欧洲使用新冠康复期血浆进行居家及院外治疗
Life (Basel). 2022 Oct 26;12(11):1704. doi: 10.3390/life12111704.
9
Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia.一名新冠病毒肺炎慢性淋巴细胞白血病患者接受恢复期血浆治疗后的临床及病毒学反应
Life (Basel). 2022 Jul 21;12(7):1098. doi: 10.3390/life12071098.
10
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.治疗或预防 SARS-CoV-2 感染延长和严重阶段的 B 细胞耗竭剂的临床管理：定义治疗途径。
Front Immunol. 2022 May 27;13:911339. doi: 10.3389/fimmu.2022.911339. eCollection 2022.

本文引用的文献

1
Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia.新冠肺炎肺炎患者恢复期血浆治疗时机与 28 天死亡率的关系。
J Investig Med. 2022 Jun;70(5):1258-1264. doi: 10.1136/jim-2021-002158. Epub 2022 Feb 8.
2
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.SARS-CoV-2 从高中和性的 COVID-19 恢复期血浆中逃逸。
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2103154118.
3
Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.SARS-CoV-2 在患有非霍奇金淋巴瘤的免疫功能低下患者中的长期进化。
mSphere. 2021 Aug 25;6(4):e0024421. doi: 10.1128/mSphere.00244-21. Epub 2021 Jul 28.
4
Urgent Need to Regulate Convalescent Plasma Differently from Thawed Plasma.迫切需要对恢复期血浆与解冻血浆进行不同的管理。
Transfus Med Hemother. 2021 Mar;48(2):132-133. doi: 10.1159/000513035. Epub 2020 Dec 21.
5
Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series.在体液免疫受损且持续 SARS-CoV-2 感染的儿童和年轻成年人中，病毒变异增加：一项连续病例系列研究。
EBioMedicine. 2021 May;67:103355. doi: 10.1016/j.ebiom.2021.103355. Epub 2021 Apr 26.
6
Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.用恢复期血浆和基于血浆的产品治疗 B 细胞耗竭的 COVID-19 患者。
Clin Immunol. 2021 Jun;227:108723. doi: 10.1016/j.clim.2021.108723. Epub 2021 Apr 7.
7
Temporal dynamics of SARS-CoV-2 mutation accumulation within and across infected hosts.感染宿主内和宿主间 SARS-CoV-2 突变积累的时间动态。
PLoS Pathog. 2021 Apr 7;17(4):e1009499. doi: 10.1371/journal.ppat.1009499. eCollection 2021 Apr.
8
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19.恢复期血浆输注对免疫功能低下的COVID-19患者的潜在益处。
Lancet Microbe. 2021 Apr;2(4):e138. doi: 10.1016/S2666-5247(21)00030-6. Epub 2021 Mar 30.
9
COVID-19 convalescent plasma therapy: hit fast, hit hard!新冠康复者血浆疗法：速战速决，重拳出击！
Vox Sang. 2021 Oct;116(9):935-942. doi: 10.1111/vox.13091. Epub 2021 Apr 1.
10
Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.用恢复期血浆治疗体液免疫缺陷患者的新型冠状病毒肺炎——三例连续病例及文献综述
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Feb 11;40(9):507-16. doi: 10.1016/j.eimc.2021.01.013.

恢复期血浆在免疫功能低下和脆弱人群中预防和治疗 SARS-CoV-2 的潜在用途。

Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.

机构信息

North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.

出版信息

Expert Rev Vaccines. 2022 Jul;21(7):877-884. doi: 10.1080/14760584.2021.1932475. Epub 2021 May 27.

DOI:10.1080/14760584.2021.1932475
PMID:34015243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8171015/
Abstract

INTRODUCTION

: The ongoing SARS-CoV-2 pandemic is a serious threat for the health of immunocompromised patients. Among neutralizing antibody-based therapeutics, convalescent plasma containing polyclonal anti-SARS-CoV-2 immunoglobulins has promising results in both congenital and iatrogenic immunodeficiencies in oncohematological and transplant patients.

AREAS COVERED

: This article discusses case reports, case series and controlled studies detailing the efficacy of convalescent plasma in immunocompromised patients.

EXPERT OPINION

: Convalescent plasma, when administered at high neutralizing antibody titers, is a safe and effective treatment for frail immunocompromised patients. Genetic monitoring of refractory patients is recommended to intercept intra-host emergence of SARS-CoV-2 variants.

摘要

简介

持续的 SARS-CoV-2 大流行对免疫功能低下患者的健康构成严重威胁。在基于中和抗体的治疗方法中，含有 SARS-CoV-2 多克隆中和抗体的恢复期血浆在血液肿瘤和移植患者的先天性和医源性免疫缺陷中具有良好的效果。

涵盖领域

本文讨论了详细介绍恢复期血浆在免疫功能低下患者中的疗效的病例报告、病例系列和对照研究。

专家意见

当恢复期血浆中的中和抗体滴度较高时，对虚弱的免疫功能低下患者是一种安全有效的治疗方法。建议对难治性患者进行基因监测，以拦截 SARS-CoV-2 变异株在体内的出现。